Using CRISPR-Cas9, Cooper et al. generated CD7-redirected CAR-Ts deficient in the expression of CD7 and TCR alpha chain (TRAC) that demonstrated effective tumoricidal activity against T-ALL primary cell samples and cell lines and suppressed tumor progression in PDX preclinical models without graft-versus-host disease (GvHD) mediation [59]. The gene discussed is CD7; the disease is acute lymphoblastic leukemia.